Allogene Therapeutics Inc (NASDAQ:ALLO) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 12,830,000 shares, a growth of 9.6% from the December 15th total of 11,710,000 shares. Approximately 26.9% of the shares of the stock are sold short. Based on an average daily volume of 537,500 shares, the days-to-cover ratio is currently 23.9 days.
Hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. bought a new stake in shares of Allogene Therapeutics in the 3rd quarter worth approximately $996,000. Virtu Financial LLC bought a new stake in shares of Allogene Therapeutics in the 3rd quarter worth approximately $246,000. SG Americas Securities LLC bought a new stake in shares of Allogene Therapeutics in the 3rd quarter worth approximately $1,046,000. AXA grew its position in shares of Allogene Therapeutics by 66.6% in the 2nd quarter. AXA now owns 172,058 shares of the company’s stock worth $4,620,000 after buying an additional 68,773 shares during the last quarter. Finally, California Public Employees Retirement System grew its position in shares of Allogene Therapeutics by 409.2% in the 3rd quarter. California Public Employees Retirement System now owns 98,272 shares of the company’s stock worth $2,678,000 after buying an additional 78,972 shares during the last quarter. Hedge funds and other institutional investors own 55.52% of the company’s stock.
Several equities analysts have recently commented on ALLO shares. William Blair reiterated a “buy” rating on shares of Allogene Therapeutics in a research report on Tuesday, November 5th. JPMorgan Chase & Co. reiterated a “hold” rating and set a $29.00 price objective on shares of Allogene Therapeutics in a research report on Wednesday, November 6th. JMP Securities started coverage on Allogene Therapeutics in a research report on Wednesday, December 18th. They set an “outperform” rating and a $37.00 price target on the stock. ValuEngine upgraded Allogene Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, December 30th. Finally, Canaccord Genuity started coverage on Allogene Therapeutics in a research report on Monday, November 4th. They set a “buy” rating and a $36.00 price target on the stock. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $36.20.
ALLO opened at $26.62 on Thursday. The stock’s 50 day simple moving average is $27.34 and its 200 day simple moving average is $27.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 15.28 and a current ratio of 15.28. Allogene Therapeutics has a 1 year low of $24.60 and a 1 year high of $33.80.
Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.50) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.04. Analysts expect that Allogene Therapeutics will post -1.93 EPS for the current fiscal year.
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Featured Story: Neutral Rating
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.